Overview

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Status:
Not yet recruiting

Trial end date:
2025-07-15

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Dermira, Inc.